Androgen Receptor, EGFR, and BRCA1 As Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis

Li Zhang,Cheng Fang,Xing Xu,Anling Li,Qing Cai,Xinghua Long
DOI: https://doi.org/10.1155/2015/357485
2015-01-01
BioMed Research International
Abstract:Objective . More and more evidences demonstrate that androgen receptor (AR), epidermal growth factor receptor (EGFR), and breast cancer susceptibility gene 1 (BRCA1) have unique clinical implications for targeted therapy or prognosis in triple-negative breast cancer (TNBC). Therefore, we conducted a meta-analysis to summarize the possible associations. Methods . We retrieved published articles about AR, EGFR, and BRCA1 in TNBC from PubMed and EMBASE. The analysis was performed with Rev-Man 5.2 software. Results . A total of 38 articles were eligible for the meta-analysis. Our study showed that the expression level of EGFR (OR=6.88,P<0.00001) and the prevalence of BRCA1 mutation (RR=5.26,P<0.00001) were higher in TNBC than non-TNBC. In contrast, the expression level of AR was lower in TNBC than non-TNBC (OR=0.07,P<0.00001). In the subgroup related to EGFR expression, the level of EGFR expression was significantly increased in Asians (OR=9.60) compared with Caucasians (OR=5.53) for TNBC patients. Additionally, the prevalence of BRCA1 mutation in Asians (RR=5.43,P<0.00001) was higher than that in Caucasians (RR=5.16,P<0.00001). Conclusions . The distinct expression of AR and EGFR and the prevalence of BRCA1 mutation indicated that AR, EGFR, and BRCA1 might be unique biomarkers for targeted therapy and prognosis in TNBC.
What problem does this paper attempt to address?